ImmunityBio (IBRX) Net Equity Issued and Repurchased (2014 - 2025)

ImmunityBio (IBRX) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $53.7 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 215076.0% year-over-year to $53.7 million in Q4 2025; TTM through Dec 2025 was $227.4 million, a 6216.69% increase from a year earlier, with the FY2025 full-year figure at $400.6 million, up 11026.72% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $53.7 million, down from $173.7 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for IBRX reached as high as $173.7 million in Q3 2025 and fell as low as -$91.2 million in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $30.3 million across 5 years, with a median of $27.6 million in 2021.
• Across the five-year window, Net Equity Issued and Repurchased sank 250.93% in 2023 and surged 215076.0% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $27.6 million in 2021, then surged by 119.08% to $60.4 million in 2022, then sank by 250.93% to -$91.2 million in 2023, then soared by 99.97% to -$25000.0 in 2024, then jumped by 215076.0% to $53.7 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $53.7 million in Q4 2025, $173.7 million in Q3 2025, and -$25000.0 in Q4 2024.